Startsida
Hjälp
Sök i LIBRIS databas

     

 

Sökning: onr:7hwdzpkr5rbmrgs9 > The Molecular Adsor...

The Molecular Adsorbent Recirculating System in Posthepatectomy Liver Failure [Elektronisk resurs] Results From a Prospective Phase I Study

Gilg, Stefan (författare)
Sparrelid, Ernesto (författare)
Saraste, Lars (författare)
Nowak, Greg (författare)
Wahlin, Staffan (författare)
Stromberg, Cecilia (författare)
Lundell, Lars (författare)
Isaksson, Bengt (författare)
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet (utgivare)
Publicerad: JOHN WILEY & SONS LTD, 2018
Engelska.
Ingår i: ; 2:4, 445-454
Läs hela texten
Läs hela texten
Läs hela texten
  • E-artikel/E-kapitel
Sammanfattning Ämnesord
Stäng  
  • Posthepatectomy liver failure (PHLF) represents the single most important cause of postoperative mortality after major liver resection, yet no effective treatment option is available. Extracorporeal liver support devices might be helpful, but systematic studies are lacking. Accordingly, we aimed to assess the safety and feasibility of the Molecular Adsorbent Recirculating System (MARS) in patients with PHLF. Between December 2012 and May 2015, a total of 206 patients underwent major or extended hepatectomy, and 10 consecutive patients with PHLF (according to the Balzan 50: 50 criteria) were enrolled into the study. MARS treatment was initiated on postoperative day 5-7, and five to seven consecutive treatment sessions were completed for each patient. In total, 59 MARS cycles were implemented, and MARS was initiated and completed without major complications in any patient. However, 1 patient developed an immense asymptomatic hyperbilirubinemia (without encephalopathy), 1 had repeated clotting problems in the MARS filter, and 2 patients experienced access problems with the central venous line. Otherwise, no adverse events were observed. In 9 patients, the bilirubin level and international normalized ratio decreased significantly (P < 0.05) during MARS treatment. The 60- and 90-day mortality was 0% and 10%, respectively. Among the 9 survivors, 4 still had liver dysfunction at 90 days postoperatively. Five patients were alive 1 year postoperatively without any signs of liver dysfunction or disease recurrence. Conclusion: The use of MARS in PHLF is feasible and safe and improves liver function in patients with PHLF. In the present study, 60- and 90-day mortality rates were unexpectedly low compared to a historical control group. The impact of MARS treatment on mortality in PHLF should be further evaluated in a randomized controlled clinical trial. 

Ämnesord

Medical and Health Sciences  (hsv)
Clinical Medicine  (hsv)
Surgery  (hsv)
Medicin och hälsovetenskap  (hsv)
Klinisk medicin  (hsv)
Kirurgi  (hsv)
Medical and Health Sciences  (hsv)
Clinical Medicine  (hsv)
Gastroenterology and Hepatology  (hsv)
Medicin och hälsovetenskap  (hsv)
Klinisk medicin  (hsv)
Gastroenterologi  (hsv)

Genre

government publication  (marcgt)
Inställningar Hjälp

Beståndsinformation saknas

Om LIBRIS
Sekretess
Blogg
Hjälp
Fel i posten?
Kontakt
Teknik och format
Sök utifrån
Sökrutor
Plug-ins
Bookmarklet
Anpassa
Textstorlek
Kontrast
Vyer
LIBRIS söktjänster
SwePub
Sondera
Uppsök

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy